BioNTech (NASDAQ:BNTX) Price Target Raised to $132.00

BioNTech (NASDAQ:BNTX) had its price target boosted by TD Cowen from $85.00 to $132.00 in a research report report published on Monday morning, Benzinga reports. They currently have a hold rating on the stock.

A number of other brokerages have also recently issued reports on BNTX. HC Wainwright raised their target price on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, October 7th. UBS Group raised their price target on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. upgraded BioNTech from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $91.00 to $125.00 in a research report on Monday, September 16th. Bank of America increased their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Finally, Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $135.54.

BioNTech Price Performance

Shares of BNTX opened at $110.98 on Monday. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The firm has a market cap of $26.38 billion, a price-to-earnings ratio of 221.96 and a beta of 0.24. The stock has a 50 day moving average of $105.74 and a 200-day moving average of $94.52.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. During the same period in the prior year, the firm earned ($0.86) EPS. The business’s revenue for the quarter was down 23.3% compared to the same quarter last year. As a group, analysts forecast that BioNTech will post -3.04 EPS for the current year.

Institutional Trading of BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after acquiring an additional 111 shares during the period. Covestor Ltd boosted its stake in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares in the last quarter. Midwest Professional Planners LTD. increased its position in shares of BioNTech by 7.2% during the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after purchasing an additional 212 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of BioNTech by 2.3% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock worth $904,000 after buying an additional 223 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.